KAHR Medical
Fusion Proteins for Treating Cancer and Autoimmune Diseases
Company Overview
Snapshot
Founded in September 2005, KAHR Medical operates with 11–50 employees and has raised a total of $118.27 million across 12 funding rounds from 17 investors.
Business overview
KAHR Medical is a clinical-stage biotechnology company focused on developing immuno-oncology drug candidates for the treatment of various cancers. Its core technology is based on multifunctional immuno-recruitment proteins (MIRP) that selectively target and bind to tumors, combining immune checkpoint inhibition with localized immune cell activation. This approach aims to unmask cancer cell camouflage and recruit the adaptive immune system to eliminate cancer cells. The company serves the pharmaceutical and healthcare industries, particularly in the areas of cancer and autoimmune diseases, with products like DSP107, DSP105, DSP502, and DSP216.
Strategic signal
In January 2026, KAHR Bio announced strong topline Phase 2 results for its lead candidate DSP107 in combination with anti-PD-L1 therapy for colorectal cancer. This positive clinical data provides significant validation for KAHR's MIRP platform and its potential to deliver effective treatments for advanced solid tumors, signaling strong progress towards commercialization and de-risking future development for investors.
Log in to access full profile ›Company Intelligence Q&A
- What were the recent clinical trial results for DSP107?
- In January 2026, KAHR Bio announced strong topline Phase 2 results for DSP107 in combination with anti-PD-L1 therapy in patients with colorectal cancer.
- What was the outcome of the Phase I trial for DSP107 in combination with anti-PD-L1?
- In May 2023, KAHR reported dose escalation results from its Phase I trial of DSP107 in combination with anti-PD-L1 in patients with advanced solid tumors.
- When did KAHR Medical receive FDA clearance for clinical trials?
- In August 2020, KAHR Medical received FDA clearance to begin clinical trials on its immunotherapy drug to battle cancer.
- What strategic partnership did KAHR Medical form in June 2021?
- In June 2021, Samsung Biologics and KAHR Medical announced a development and manufacturing agreement for KAHR's cancer immunotherapy drug candidate.